Corporate - Media & Press - Press Release
Arrayit Corporation Completes Proteomics Platform Installation and Training at the National Institutes of Health
Cytokine Protein Microarrays Advance Study of Autoimmune Diseases and Neuropyschiatric Disorders
Press Release Source: Arrayit Corporation On Monday September 20, 2010, 12:55 pm
SUNNYVALE, Calif., Sept. 20, 2010 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC - News) has completed installation and technical training of its proprietary microarray platform at the National Institute of Mental Health, National Institutes of Health, in Rockville, Maryland. In 2010, the NIH will invest more than $31.2 billion in medical research for the American people through 50,000 competitive grants to 325,000 researchers at 3,000 universities, hospitals, companies, medical schools and scientific institutions in the United States and around the world. The mission of the NIH is to enhance human health, lengthen life, and reduce the burdens of illness and disability by making fundamental scientific advances.
Arrayit microarray technology empowers NIH researchers to rapidly detect in a highly sensitive manner human cytokines, a large class of proteins involved in immune system function. Cytokines have been implicated in major human diseases including rheumatoid arthritis, lupus, psoriasis, multiple sclerosis, diabetes, depression, schizophrenia and Alzheimer's Disease. Arrayit microarrays, tiny devices containing cytokine protein binding agents, could facilitate treatments and eventual cures for cytokine-related illnesses by allowing clinicians to quantitatively measure and correlate cytokine levels in patients afflicted with these illnesses. The NIH purchases Arrayit microarray instruments, hardware, software, reagents and consumable products. Arrayit offers a competitive advantage over other companies by combining speed, sensitivity, flexibility and cost-effectiveness in a single cytokine detection platform.
Arrayit CEO and Chairman Rene Schena states, "We believe that treatments and cures for autoimmune and neuropsychiatric diseases will be discovered by first deciphering the fundamental molecular basis of each illness. Arrayit is pleased to install this leading edge technology at the National Institutes of Health and train research scientists in furtherance of these important goals."
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 800 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises, including a broad network of international distributors. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2010 and Form 10-Q for the fiscal quarters ended March 31, 2010 and June 30, 2010.
Copyright 1993-2017 Arrayit Corporation. All rights reserved.